# Rodrigo M Mendes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6534029/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 225 papers | 9,088 citations | 36303 51 h-index | 64796 79 g-index |
| 227 all docs | 227 docs citations | 227 times ranked | 7007 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018â€“2020). Diagnostic Microbiology and Infectious Disease, 2022, 102, 115557. | 1.8 | 21 |
| 2 | In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized Î²-lactamase genes. Journal of Antimicrobial Chemotherapy, 2022, 77, 689-694. | 3.0 | 6 |
| 3 | Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010â€“2019). Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0166721. | 3.2 | 6 |
| 4 | Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019â€“2020). European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 477-487. | 2.9 | 12 |
| 5 | Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019. International Journal of Infectious Diseases, 2022, 116, 306-312. | 3.3 | 2 |
| 6 | In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program. Microbiology Spectrum, 2022, 10, e0271221. | 3.0 | 34 |
| 7 | Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018â€“2020). European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 867-873. | 2.9 | 5 |
| 8 | Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020. Diagnostic Microbiology and Infectious Disease, 2022, 103, 115713. | 1.8 | 2 |
| 9 | Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus,) Tj ETQq1 1 0.784314 rgBT /Overlock 1<br>United States hospitals in 2017â€“2019. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115195. | 1.8 | 9 |
| 10 | Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010â€“2019). International Journal of Infectious Diseases, 2021, 102, 524-528. | 3.3 | 6 |
| 11 | Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by species. Journal of Global Antimicrobial Resistance, 2021, 24, 48-52. | 2.2 | 5 |
| 12 | Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. Journal of Antimicrobial Chemotherapy, 2021, 76, 2833-2838. | 3.0 | 13 |
| 13 | Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017â€“2019). International Journal of Infectious Diseases, 2021, 107, 92-100. | 3.3 | 9 |
| 14 | Antimicrobial activity of dalbavancin and comparators against Staphylococcus aureus causing pneumonia in patients with and without cystic fibrosis. International Journal of Infectious Diseases, 2021, 107, 69-71. | 3.3 | 1 |
| 15 | Characterization of a vga gene variant recovered from a Staphylococcus saprophyticus causing a community-acquired urinary tract infection: report from the SENTRY Antimicrobial Surveillance Program 2017. Diagnostic Microbiology and Infectious Disease, 2021, 100, 115398. | 1.8 | 0 |
| 16 | Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates. Journal of Antimicrobial Chemotherapy, 2021, 76, 3125-3134. | 3.0 | 33 |
| 17 | Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. International Journal of Antimicrobial Agents, 2021, 58, 106439. | 2.5 | 36 |
| 18 | In vitro activity of a novel aminomethylcycline antibacterial (KBP-7072), a third-generation tetracycline, against clinical isolates with molecularly characterized tetracycline resistance mechanisms. JAC-Antimicrobial Resistance, 2021, 3, dlab177. | 2.1 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014â€“2016. Journal of Global Antimicrobial Resistance, 2020, 20, 118-123. | 2.2 | 4 |
| 20 | Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of Î²-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens. Microbial Drug Resistance, 2020, 26, 319-328. | 2.0 | 11 |
| 21 | In Vitro Activity Analysis of a New Polymyxin, SPR741, Tested in Combination with Antimicrobial Agents against a Challenge Set of Enterobacteriaceae , Including Molecularly Characterized Strains. Antimicrobial Agents and Chemotherapy, 2020, 65, . | 3.2 | 5 |
| 22 | Resistance among urinary tract pathogens collected in Europe during 2018. Journal of Global Antimicrobial Resistance, 2020, 23, 439-444. | 2.2 | 18 |
| 23 | Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 2009â€'2017. Journal of Infection, 2020, 81, 557-566. | 3.3 | 33 |
| 24 | Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 21 |
| 25 | Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms. Diagnostic Microbiology and Infectious Disease, 2020, 97, 115054. | 1.8 | 3 |
| 26 | Media for colistin susceptibility testing does not improve the detection of Klebsiella pneumoniae isolates carrying MgrB disruption and other mutation driven colistin resistance mechanisms. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115077. | 1.8 | 4 |
| 27 | Comparison of minimum inhibitory concentration results for gepotidacin obtained using agar dilution and broth microdilution methods. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115107. | 1.8 | 8 |
| 28 | Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014â€“2018): therapeutic options for multidrug-resistant bacteria. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115108. | 1.8 | 15 |
| 29 | Antimicrobial Activity of Telavancin Tested In Vitro Against a Global Collection of Gram-Positive Pathogens, Including Multidrug-Resistant Isolates (2015â€“2017). Microbial Drug Resistance, 2020, 26, 934-943. | 2.0 | 8 |
| 30 | Assessment of Tedizolid In Vitro Activity and Resistance Mechanisms against a Collection of Enterococcus spp. Causing Invasive Infections, Including Isolates Requiring an Optimized Dosing Strategy for Daptomycin from U.S. and European Medical Centers, 2016 to 2018. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 12 |
| 31 | Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 44 |
| 32 | Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 12 |
| 33 | Activity of Plazomicin Tested against Enterobacterales Isolates Collected from U.S. Hospitals in 2016â€“2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 14 |
| 34 | Updating Molecular Diagnostics for Detecting Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Isolates in Blood Culture Bottles. Journal of Clinical Microbiology, 2019, 57, . | 3.9 | 26 |
| 35 | Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015â€“2016 and Characterization of Resistance Mechanisms. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 25 |
| 36 | In Vitro Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014â€“2015) in the United States. Microbial Drug Resistance, 2019, 25, 938-943. | 2.0 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions. Diagnostic Microbiology and Infectious Disease, 2019, 94, 73-77. | 1.8 | 16 |
| 38 | Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals. Journal of Antimicrobial Chemotherapy, 2019, 74, 2588-2595. | 3.0 | 34 |
| 39 | Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014â€“2015). Journal of Chemotherapy, 2019, 31, 188-194. | 1.5 | 18 |
| 40 | Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum Î²-Lactamases from U.S. Hospitals. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 37 |
| 41 | The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 307 |
| 42 | Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997â€“2016. Open Forum Infectious Diseases, 2019, 6, S54-S62. | 0.9 | 70 |
| 43 | Antimicrobial Resistance Surveillance and New Drug Development. Open Forum Infectious Diseases, 2019, 6, S5-S13. | 0.9 | 10 |
| 44 | Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program. Open Forum Infectious Diseases, 2019, 6, S23-S33. | 0.9 | 124 |
| 45 | Application of Next-Generation Sequencing for Characterization of Surveillance and Clinical Trial Isolates: Analysis of the Distribution of Î²-lactamase Resistance Genes and Lineage Background in the United States. Open Forum Infectious Diseases, 2019, 6, S69-S78. | 0.9 | 45 |
| 46 | Characterization of Î²-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against Î²-Lactamase Producers. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 21 |
| 47 | Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997â€“2016). Open Forum Infectious Diseases, 2019, 6, S14-S23. | 0.9 | 56 |
| 48 | Aminoglycoside-modifying enzyme and 16S ribosomal RNA methyltransferase genes among a global collection of Gram-negative isolates. Journal of Global Antimicrobial Resistance, 2019, 16, 278-285. | 2.2 | 30 |
| 49 | Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 27 |
| 50 | Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014â€“17). Journal of Antimicrobial Chemotherapy, 2019, 74, 1928-1933. | 3.0 | 12 |
| 51 | Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres. Journal of Antimicrobial Chemotherapy, 2019, 74, 1306-1310. | 3.0 | 21 |
| 52 | Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016â€“2017). Diagnostic Microbiology and Infectious Disease, 2019, 94, 304-313. | 1.8 | 19 |
| 53 | The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017. PLoS ONE, 2019, 14, e0220265. | 2.5 | 94 |
| 54 | In vitro activity of tedizolid against clinical isolates of Staphylococcus lugdunensis and Staphylococcus haemolyticus from Europe and the United States. Diagnostic Microbiology and Infectious Disease, 2019, 93, 85-88. | 1.8 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012â€“2016). Diagnostic Microbiology and Infectious Disease, 2019, 93, 167-170. | 1.8 | 0 |
| 56 | Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 32 |
| 57 | In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. International Journal of Antimicrobial Agents, 2018, 52, 144-150. | 2.5 | 77 |
| 58 | Molecular Î²-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets. International Journal of Antimicrobial Agents, 2018, 52, 287-292. | 2.5 | 26 |
| 59 | ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries. Journal of Antimicrobial Chemotherapy, 2018, 73, 1880-1887. | 3.0 | 56 |
| 60 | Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011â€“2016). International Journal of Antimicrobial Agents, 2018, 51, 608-611. | 2.5 | 46 |
| 61 | Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 46 |
| 62 | Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 18 |
| 63 | Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014â€“16). Journal of Antimicrobial Chemotherapy, 2018, 73, 916-922. | 3.0 | 2 |
| 64 | Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010â€“2014. Diagnostic Microbiology and Infectious Disease, 2018, 91, 199-204. | 1.8 | 20 |
| 65 | Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 61 |
| 66 | In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016). Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 15 |
| 67 | Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010â€“2016): concomitant analysis of oritavancinin vitroactivity. Journal of Chemotherapy, 2018, 30, 280-289. | 1.5 | 28 |
| 68 | Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America. International Journal of Infectious Diseases, 2018, 77, 82-86. | 3.3 | 22 |
| 69 | Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates. Journal of Clinical Microbiology, 2018, 56, . | 3.9 | 8 |
| 70 | Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015â€“17). Journal of Antimicrobial Chemotherapy, 2018, 73, 3053-3059. | 3.0 | 55 |
| 71 | Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015â€“16. Journal of Antimicrobial Chemotherapy, 2018, 73, 2748-2756. | 3.0 | 47 |
| 72 | In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 67 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 24 |
| 74 | Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011â€“2014). European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1013-1017. | 2.9 | 12 |
| 75 | Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals. Pediatric Infectious Disease Journal, 2017, 36, 486-491. | 2.0 | 19 |
| 76 | Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to) Tj ETQq0 0 0 rgBT /Overlock 10 Tf | 3.2 | 60 |
| 77 | Empyema thoracis caused by an optrA -positive and linezolid-intermediate Enterococcus faecalis strain. Journal of Infection, 2017, 75, 182-184. | 3.3 | 8 |
| 78 | Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 29 |
| 79 | Molecular Î²-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 31 |
| 80 | Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations. Diagnostic Microbiology and Infectious Disease, 2017, 88, 184-187. | 1.8 | 13 |
| 81 | Ceftaroline Activity Against Multidrug-Resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and Molecular Characterization of a Single Ceftaroline Nonsusceptible Isolate. Microbial Drug Resistance, 2017, 23, 571-579. | 2.0 | 11 |
| 82 | Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying bla <sub>KPC</sub> Collected in U.S. Hospitals from 2012 to 2015. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 47 |
| 83 | Prevalence of macrolideâ€“lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. Journal of Global Antimicrobial Resistance, 2017, 8, 28-32. | 2.2 | 8 |
| 84 | Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 89 |
| 85 | In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions. Microbial Drug Resistance, 2017, 23, 718-726. | 2.0 | 10 |
| 86 | ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries. Journal of Antimicrobial Chemotherapy, 2017, 72, 3093-3099. | 3.0 | 31 |
| 87 | Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014â€“2015). Journal of Global Antimicrobial Resistance, 2017, 11, 4-7. | 2.2 | 9 |
| 88 | Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014). Journal of Global Antimicrobial Resistance, 2017, 10, 271-276. | 2.2 | 16 |
| 89 | Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 141 |
| 90 | Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016). Open Forum Infectious Diseases, 2017, 4, S368-S368. | 0.9 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Evolution of Ceftaroline-Resistant Mrsa in a Child with Cystic Fibrosis Following Repeated Antibiotic Exposure. Pediatric Infectious Disease Journal, 2016, 35, 813-815. | 2.0 | 16 |
| 92 | Detection of mcr-1 among Escherichia coli Clinical Isolates Collected Worldwide as Part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015. Antimicrobial Agents and Chemotherapy, 2016, 60, 5623-5624. | 3.2 | 100 |
| 93 | Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014. Antimicrobial Agents and Chemotherapy, 2016, 60, 2558-2563. | 3.2 | 13 |
| 94 | Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014. Antimicrobial Agents and Chemotherapy, 2016, 60, 5393-5399. | 3.2 | 32 |
| 95 | Surveillance for linezolid resistance via the Zyvox<sup>Â®</sup>Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates. Journal of Antimicrobial Chemotherapy, 2016, 71, 1860-1865. | 3.0 | 63 |
| 96 | In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011â€“2013). International Journal of Antimicrobial Agents, 2016, 47, 495-499. | 2.5 | 16 |
| 97 | Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011â€“2014). International Journal of Antimicrobial Agents, 2016, 48, 144-150. | 2.5 | 52 |
| 98 | Changes in the Frequencies of Î²-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against Î²-Lactamase-Producing Isolates. Antimicrobial Agents and Chemotherapy, 2016, 60, 4770-4777. | 3.2 | 53 |
| 99 | Comparison of BD Max StaphSR and BD Max MRSA XT for Screening of Staphylococcus aureus Clinical Isolates Collected from Hospitals in the United States. Journal of Clinical Microbiology, 2016, 54, 1668-1669. | 3.9 | 1 |
| 100 | Ceftaroline activity tested against viridans group streptococci from US hospitals. Diagnostic Microbiology and Infectious Disease, 2016, 84, 232-235. | 1.8 | 6 |
| 101 | Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014). Antimicrobial Agents and Chemotherapy, 2016, 60, 3419-3425. | 3.2 | 4 |
| 102 | Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals. Diagnostic Microbiology and Infectious Disease, 2016, 85, 80-84. | 1.8 | 19 |
| 103 | In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States. Antimicrobial Agents and Chemotherapy, 2016, 60, 4407-4411. | 3.2 | 38 |
| 104 | Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013â€“2014). Diagnostic Microbiology and Infectious Disease, 2016, 86, 300-302. | 1.8 | 6 |
| 105 | Longitudinal (2001â€“14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010â€“13) analysis of oritavancin in vitro potency. Journal of Antimicrobial Chemotherapy, 2016, 71, 3453-3458. | 3.0 | 71 |
| 106 | Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013â€“2014). Diagnostic Microbiology and Infectious Disease, 2016, 86, 303-306. | 1.8 | 10 |
| 107 | Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014. Antimicrobial Agents and Chemotherapy, 2016, 60, 3827-3831. | 3.2 | 22 |
| 108 | Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012â€“2014). Diagnostic Microbiology and Infectious Disease, 2016, 86, 76-79. | 1.8 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011â€“2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin. Journal of Chemotherapy, 2016, 28, 83-88. | 1.5 | 9 |
| 110 | Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model. Antimicrobial Agents and Chemotherapy, 2016, 60, 2075-2080. | 3.2 | 40 |
| 111 | Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014). Diagnostic Microbiology and Infectious Disease, 2016, 86, 249-251. | 1.8 | 4 |
| 112 | Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results. Antimicrobial Agents and Chemotherapy, 2016, 60, 3817-3820. | 3.2 | 2 |
| 113 | Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014). Antimicrobial Agents and Chemotherapy, 2016, 60, 2273-2280. | 3.2 | 80 |
| 114 | Î²-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates. Antimicrobial Agents and Chemotherapy, 2016, 60, 1328-1335. | 3.2 | 24 |
| 115 | In vivoemergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis: TableÂ1.. Journal of Antimicrobial Chemotherapy, 2016, 71, 1736-1738. | 3.0 | 18 |
| 116 | Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility. Antimicrobial Agents and Chemotherapy, 2016, 60, 3174-3177. | 3.2 | 14 |
| 117 | Performance of BD Max StaphSR for Screening of Methicillin-Resistant Staphylococcus aureus Isolates among a Contemporary and Diverse Collection from 146 Institutions Located in Nine U.S. Census Regions: Prevalence of mecA Dropout Mutants. Journal of Clinical Microbiology, 2016, 54, 204-207. | 3.9 | 15 |
| 118 | Genotypic Characterization of Methicillin-ResistantStaphylococcus aureusRecovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole. Microbial Drug Resistance, 2016, 22, 53-58. | 2.0 | 5 |
| 119 | Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011â€“13): Table 1.. Journal of Antimicrobial Chemotherapy, 2016, 71, 276-278. | 3.0 | 20 |
| 120 | Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013. Antimicrobial Agents and Chemotherapy, 2015, 59, 3656-3659. | 3.2 | 74 |
| 121 | In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program. Antimicrobial Agents and Chemotherapy, 2015, 59, 5007-5009. | 3.2 | 44 |
| 122 | Noninvasive Streptococcus pneumoniae Serotypes Recovered from Hospitalized Adult Patients in the United States in 2009 to 2012. Antimicrobial Agents and Chemotherapy, 2015, 59, 5595-5601. | 3.2 | 24 |
| 123 | Detection of a New cfr -Like Gene, cfr (B), in Enterococcus faecium Isolates Recovered from Human Specimens in the United States as Part of the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2015, 59, 6256-6261. | 3.2 | 124 |
| 124 | Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. Diagnostic Microbiology and Infectious Disease, 2015, 82, 78-84. | 1.8 | 16 |
| 125 | Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010â€“2013). Diagnostic Microbiology and Infectious Disease, 2015, 83, 183-186. | 1.8 | 58 |
| 126 | Cytotoxic Virulence Predicts Mortality in Nosocomial Pneumonia Due to Methicillin-ResistantStaphylococcus aureus. Journal of Infectious Diseases, 2015, 211, 1862-1874. | 4.0 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. Diagnostic Microbiology and Infectious Disease, 2015, 81, 283-289. | 1.8 | 25 |
| 128 | Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. International Journal of Antimicrobial Agents, 2015, 46, 53-59. | 2.5 | 75 |
| 129 | Telavancin In Vitro Activity against a Collection of Methicillin-Resistant Staphylococcus aureus Isolates, Including Resistant Subsets, from the United States. Antimicrobial Agents and Chemotherapy, 2015, 59, 1811-1814. | 3.2 | 24 |
| 130 | Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011â€“2013). Journal of Global Antimicrobial Resistance, 2015, 3, 36-39. | 2.2 | 3 |
| 131 | Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. Diagnostic Microbiology and Infectious Disease, 2015, 81, 275-279. | 1.8 | 42 |
| 132 | Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagnostic Microbiology and Infectious Disease, 2015, 82, 73-77. | 1.8 | 34 |
| 133 | Use of In Vitro Vancomycin Testing Results To Predict Susceptibility to Oritavancin, a New Long-Acting Lipoglycopeptide. Antimicrobial Agents and Chemotherapy, 2015, 59, 2405-2409. | 3.2 | 18 |
| 134 | Update on Linezolid In Vitro Activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013. Antimicrobial Agents and Chemotherapy, 2015, 59, 2454-2457. | 3.2 | 17 |
| 135 | Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin. Journal of Clinical Microbiology, 2015, 53, 2727-2730. | 3.9 | 8 |
| 136 | MSSA ST398/t034 carrying a plasmid-mediated Cfr and Erm(B) in Brazil. Journal of Antimicrobial Chemotherapy, 2015, 70, 303-305. | 3.0 | 22 |
| 137 | Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13). Journal of Antimicrobial Chemotherapy, 2015, 70, 498-504. | 3.0 | 32 |
| 138 | Baseline Activity of Telavancin against Gram-Positive Clinical Isolates Responsible for Documented Infections in U.S. Hospitals (2011-2012) as Determined by the Revised Susceptibility Testing Method. Antimicrobial Agents and Chemotherapy, 2015, 59, 702-706. | 3.2 | 21 |
| 139 | Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. Journal of Antimicrobial Chemotherapy, 2014, 69, 1579-1581. | 3.0 | 16 |
| 140 | Oritavancin Activity against Staphylococcus aureus Causing Invasive Infections in U.S. and European Hospitals: a 5-Year International Surveillance Program. Antimicrobial Agents and Chemotherapy, 2014, 58, 2921-2924. | 3.2 | 30 |
| 141 | Revised Reference Broth Microdilution Method for Testing Telavancin: Effect on MIC Results and Correlation with Other Testing Methodologies. Antimicrobial Agents and Chemotherapy, 2014, 58, 5547-5551. | 3.2 | 42 |
| 142 | Quality Control MIC Ranges Used for Telavancin with Application of a Revised CLSI Reference Broth Microdilution Method. Journal of Clinical Microbiology, 2014, 52, 3399-3401. | 3.9 | 19 |
| 143 | Decreased Ceftriaxone Susceptibility in Emerging (35B and 6C) and Persisting (19A) Streptococcus pneumoniae Serotypes in the United States, 2011-2012: Ceftaroline Remains Active In Vitro among Î²-Lactam Agents. Antimicrobial Agents and Chemotherapy, 2014, 58, 4923-4927. | 3.2 | 19 |
| 144 | Ceftaroline Activity Tested Against Bacterial Isolates From Pediatric Patients. Pediatric Infectious Disease Journal, 2014, 33, 837-842. | 2.0 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Relationship between Ceftolozane-Tazobactam Exposure and Selection for Pseudomonas aeruginosa Resistance in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2014, 58, 6024-6031. | 3.2 | 39 |
| 146 | Update on Acinetobacter Species: Mechanisms of Antimicrobial Resistance and Contemporary In Vitro Activity of Minocycline and Other Treatment Options. Clinical Infectious Diseases, 2014, 59, S367-S373. | 5.8 | 69 |
| 147 | Summary of Linezolid Activity and Resistance Mechanisms Detected during the 2012 LEADER Surveillance Program for the United States. Antimicrobial Agents and Chemotherapy, 2014, 58, 1243-1247. | 3.2 | 44 |
| 148 | Resistance surveillance program report for selected European nations (2011). Diagnostic Microbiology and Infectious Disease, 2014, 78, 429-436. | 1.8 | 78 |
| 149 | Linezolid update: Stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resistance Updates, 2014, 17, 1-12. | 14.4 | 195 |
| 150 | Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years (2004-12). Journal of Antimicrobial Chemotherapy, 2014, 69, 1582-1588. | 3.0 | 67 |
| 151 | Regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians!. Diagnostic Microbiology and Infectious Disease, 2014, 80, 91-92. | 1.8 | 0 |
| 152 | Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. Diagnostic Microbiology and Infectious Disease, 2014, 80, 19-25. | 1.8 | 45 |
| 153 | Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011). Diagnostic Microbiology and Infectious Disease, 2013, 77, 258-266. | 1.8 | 26 |
| 154 | Regional Resistance Surveillance Program Results for 12 Asia-Pacific Nations (2011). Antimicrobial Agents and Chemotherapy, 2013, 57, 5721-5726. | 3.2 | 74 |
| 155 | An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. Diagnostic Microbiology and Infectious Disease, 2013, 76, 206-213. | 1.8 | 57 |
| 156 | Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens. Diagnostic Microbiology and Infectious Disease, 2013, 76, 69-72. | 1.8 | 19 |
| 157 | Prevalence of Î²-Lactamase-Encoding Genes among Enterobacteriaceae Bacteremia Isolates Collected in 26 U.S. Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrobial Agents and Chemotherapy, 2013, 57, 3012-3020. | 3.2 | 100 |
| 158 | Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria. Diagnostic Microbiology and Infectious Disease, 2013, 75, 402-405. | 1.8 | 11 |
| 159 | Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998â€“2011). Diagnostic Microbiology and Infectious Disease, 2013, 75, 107-109. | 1.8 | 80 |
| 160 | Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011. Antimicrobial Agents and Chemotherapy, 2013, 57, 1077-1081. | 3.2 | 48 |
| 161 | Pharmacological Basis of Î²-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane. Antimicrobial Agents and Chemotherapy, 2013, 57, 5924-5930. | 3.2 | 62 |
| 162 | Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 2809-2814. | 3.2 | 79 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Potency and Spectrum of Activity of AN3365, a Novel Boron-Containing Protein Synthesis Inhibitor, Tested against Clinical Isolates of Enterobacteriaceae and Nonfermentative Gram-Negative Bacilli. Antimicrobial Agents and Chemotherapy, 2013, 57, 2849-2857. | 3.2 | 37 |
| 164 | Streptococcus sanguinis Isolate Displaying a Phenotype with Cross-Resistance to Several rRNA-Targeting Agents. Journal of Clinical Microbiology, 2013, 51, 2728-2731. | 3.9 | 16 |
| 165 | Rapid Expansion of KPC-2-Producing Klebsiella pneumoniae Isolates in Two Texas Hospitals due to Clonal Spread of ST258 and ST307 Lineages. Microbial Drug Resistance, 2013, 19, 295-297. | 2.0 | 54 |
| 166 | The Genetic Environment of the cfr Gene and the Presence of Other Mechanisms Account for the Very High Linezolid Resistance of Staphylococcus epidermidis Isolate 426-3147L. Antimicrobial Agents and Chemotherapy, 2013, 57, 1173-1179. | 3.2 | 36 |
| 167 | Dissemination of a pSCFS3-Like cfr -Carrying Plasmid in Staphylococcus aureus and Staphylococcus epidermidis Clinical Isolates Recovered from Hospitals in Ohio. Antimicrobial Agents and Chemotherapy, 2013, 57, 2923-2928. | 3.2 | 40 |
| 168 | Relationship between Ceftolozane-Tazobactam Exposure and Drug Resistance Amplification in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 4134-4138. | 3.2 | 38 |
| 169 | Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae Testing Susceptible to Cefepime by Reference Methods. Journal of Clinical Microbiology, 2013, 51, 2388-2390. | 3.9 | 7 |
| 170 | Worldwide Appraisal and Update (2010) of Telavancin Activity Tested against a Collection of Gram-Positive Clinical Pathogens from Five Continents. Antimicrobial Agents and Chemotherapy, 2012, 56, 3999-4004. | 3.2 | 35 |
| 171 | Oritavancin Activity against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci with Molecularly Characterized Glycopeptide Resistance Genes Recovered from Bacteremic Patients, 2009-2010. Antimicrobial Agents and Chemotherapy, 2012, 56, 1639-1642. | 3.2 | 31 |
| 172 | Oritavancin Microbiologic Features and Activity Results From the Surveillance Program in the United States. Clinical Infectious Diseases, 2012, 54, S203-S213. | 5.8 | 39 |
| 173 | Transferable Plasmid-Mediated Resistance to Linezolid Due to cfr in a Human Clinical Isolate of Enterococcus faecalis. Antimicrobial Agents and Chemotherapy, 2012, 56, 3917-3922. | 3.2 | 157 |
| 174 | In Vitro Activity of Ceftaroline Against Multidrug-Resistant Staphylococcus aureus and Streptococcus pneumoniae: A Review of Published Studies and the AWARE Surveillance Program (2008â€“2010). Clinical Infectious Diseases, 2012, 55, S206-S214. | 5.8 | 78 |
| 175 | Unmet Needs and Prospects for Oritavancin in the Management of Vancomycin-Resistant Enterococcal Infections. Clinical Infectious Diseases, 2012, 54, S233-S238. | 5.8 | 48 |
| 176 | Molecular Epidemiology of Staphylococcus epidermidis Clinical Isolates from U.S. Hospitals. Antimicrobial Agents and Chemotherapy, 2012, 56, 4656-4661. | 3.2 | 75 |
| 177 | ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries. Journal of Chemotherapy, 2012, 24, 328-337. | 1.5 | 18 |
| 178 | Characterization of Methicillin-Resistant Staphylococcus aureus Strains Recovered from a Phase IV Clinical Trial for Linezolid versus Vancomycin for Treatment of Nosocomial Pneumonia. Journal of Clinical Microbiology, 2012, 50, 3694-3702. | 3.9 | 34 |
| 179 | Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007â€“2009). Diagnostic Microbiology and Infectious Disease, 2012, 72, 113-117. | 1.8 | 21 |
| 180 | LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagnostic Microbiology and Infectious Disease, 2012, 74, 54-61. | 1.8 | 45 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Molecular characterization of vancomycin-resistant Enterococcus spp. clinical isolates recovered from hospitalized patients among several medical institutions in China. Diagnostic Microbiology and Infectious Disease, 2012, 74, 399-403. | 1.8 | 23 |
| 182 | Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More Î²-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette Chromosome mec Types. Antimicrobial Agents and Chemotherapy, 2012, 56, 4779-4785. | 3.2 | 70 |
| 183 | Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. Journal of Antimicrobial Chemotherapy, 2012, 67, 1321-1324. | 3.0 | 97 |
| 184 | Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007â€“09). Journal of Antimicrobial Chemotherapy, 2011, 66, 1409-1411. | 3.0 | 65 |
| 185 | Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. Journal of Antimicrobial Chemotherapy, 2011, 66, iii69-iii80. | 3.0 | 43 |
| 186 | Update on the telavancin activity tested against European staphylococcal clinical isolates (2009â€“2010). Diagnostic Microbiology and Infectious Disease, 2011, 71, 93-97. | 1.8 | 22 |
| 187 | Plasmid-borne vga(A)-encoding gene in methicillin-resistant Staphylococcus aureus ST398 recovered from swine and a swine farmer in the United States. Diagnostic Microbiology and Infectious Disease, 2011, 71, 177-180. | 1.8 | 18 |
| 188 | LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States. Antimicrobial Agents and Chemotherapy, 2011, 55, 3684-3690. | 3.2 | 79 |
| 189 | Early Dissemination of NDM-1- and OXA-181-Producing Enterobacteriaceae in Indian Hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrobial Agents and Chemotherapy, 2011, 55, 1274-1278. | 3.2 | 303 |
| 190 | In Vitro Antimicrobial Findings for Fusidic Acid Tested Against Contemporary (2008â€“2009) Gram-Positive Organisms Collected in the United States. Clinical Infectious Diseases, 2011, 52, S477-S486. | 5.8 | 38 |
| 191 | Comment on: Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-Â-lactamases. Journal of Antimicrobial Chemotherapy, 2011, 66, 684-685. | 3.0 | 12 |
| 192 | Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. Journal of Antimicrobial Chemotherapy, 2010, 65, 2396-2404. | 3.0 | 35 |
| 193 | In Vitro Activity of Telavancin against a Contemporary Worldwide Collection of Staphylococcus aureus Isolates. Antimicrobial Agents and Chemotherapy, 2010, 54, 2704-2706. | 3.2 | 27 |
| 194 | Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. Journal of Antimicrobial Chemotherapy, 2010, 65, iv17-iv31. | 3.0 | 61 |
| 195 | Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. Journal of Antimicrobial Chemotherapy, 2010, 65, 2329-2335. | 3.0 | 126 |
| 196 | Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid. Journal of Clinical Microbiology, 2010, 48, 568-574. | 3.9 | 40 |
| 197 | First Report of Staphylococcal Clinical Isolates in Mexico with Linezolid Resistance Caused by cfr : Evidence of In Vivo cfr Mobilization. Journal of Clinical Microbiology, 2010, 48, 3041-3043. | 3.9 | 56 |
| 198 | Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007â€“2008). International Journal of Antimicrobial Agents, 2010, 36, 374-379. | 2.5 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). Journal of Antimicrobial Chemotherapy, 2010, 65, 1353-1358. | 3.0 | 89 |
| 200 | Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102). Diagnostic Microbiology and Infectious Disease, 2010, 66, 301-307. | 1.8 | 20 |
| 201 | Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. Diagnostic Microbiology and Infectious Disease, 2010, 67, 359-368. | 1.8 | 31 |
| 202 | Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005â€“2009). Diagnostic Microbiology and Infectious Disease, 2010, 68, 307-311. | 1.8 | 41 |
| 203 | Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 ZyvoxÂ® Annual Appraisal of Potency and Spectrum program. Diagnostic Microbiology and Infectious Disease, 2010, 68, 459-467. | 1.8 | 39 |
| 204 | Daptomycin Activity Tested Against Linezolid-Nonsusceptible Gram-Positive Clinical Isolates. Microbial Drug Resistance, 2009, 15, 245-249. | 2.0 | 14 |
| 205 | Resurgence of Pseudomonas Endocarditis in Detroit, 2006-2008. Medicine (United States), 2009, 88, 294-301. | 1.0 | 53 |
| 206 | TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. Journal of Antimicrobial Chemotherapy, 2009, 63, 716-720. | 3.0 | 37 |
| 207 | Codetection of bla <sub>OXA-23</sub> -Like Gene ( bla <sub>OXA-133</sub> ) and bla <sub>OXA-58</sub> in Acinetobacter radioresistens : Report from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2009, 53, 843-844. | 3.2 | 16 |
| 208 | Case Report of Aurantimonas altamirensis Bloodstream Infection. Journal of Clinical Microbiology, 2009, 47, 514-515. | 3.9 | 17 |
| 209 | Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy. Clinical Microbiology and Infection, 2009, 15, 588-592. | 6.0 | 24 |
| 210 | Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagnostic Microbiology and Infectious Disease, 2009, 65, 392-403. | 1.8 | 76 |
| 211 | Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. Diagnostic Microbiology and Infectious Disease, 2009, 63, 415-425. | 1.8 | 22 |
| 212 | Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagnostic Microbiology and Infectious Disease, 2008, 60, 433-436. | 1.8 | 41 |
| 213 | United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagnostic Microbiology and Infectious Disease, 2008, 62, 416-426. | 1.8 | 80 |
| 214 | First Report of cfr -Mediated Resistance to Linezolid in Human Staphylococcal Clinical Isolates Recovered in the United States. Antimicrobial Agents and Chemotherapy, 2008, 52, 2244-2246. | 3.2 | 203 |
| 215 | Prevalence of and Molecular Basis for Tuberculosis Drug Resistance in the Republic of Georgia: Validation of a QIAplex System for Detection of Drug Resistance-Related Mutations. Antimicrobial Agents and Chemotherapy, 2008, 52, 725-729. | 3.2 | 35 |
| 216 | Rapid Emergence ofbla<sub>CTX-M</sub>Among Enterobacteriaceae in U.S. Medical Centers: Molecular Evaluation from the MYSTIC Program (2007). Microbial Drug Resistance, 2008, 14, 211-216. | 2.0 | 79 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Metallo-Î²-Lactamase Detection: Comparative Evaluation of Double-Disk Synergy versus Combined Disk Tests for IMP-, GIM-, SIM-, SPM-, or VIM-Producing Isolates. Journal of Clinical Microbiology, 2008, 46, 2028-2037. | 3.9 | 120 |
| 218 | Increased Antimicrobial Susceptibility Profiles among Polymyxinâ€ResistantAcinetobacter baumanniiClinical Isolates. Clinical Infectious Diseases, 2008, 46, 1324-1326. | 5.8 | 20 |
| 219 | Carbapenem-Resistant Isolates of Klebsiella pneumoniae in China and Detection of a Conjugative Plasmid ( bla <sub>KPC-2</sub> plus qnrB4 ) and a bla <sub>IMP-4</sub> Gene. Antimicrobial Agents and Chemotherapy, 2008, 52, 798-799. | 3.2 | 53 |
| 220 | Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. Journal of Antimicrobial Chemotherapy, 2008, 63, 55-59. | 3.0 | 139 |
| 221 | Characterization of an Integron Carrying bla IMP-1 and a New Aminoglycoside Resistance Gene, aac(6â€²)-31 , and Its Dissemination among Genetically Unrelated Clinical Isolates in a Brazilian Hospital. Antimicrobial Agents and Chemotherapy, 2007, 51, 2611-2614. | 3.2 | 60 |
| 222 | Rapid Detection and Identification of Metallo-Î²-Lactamase-Encoding Genes by Multiplex Real-Time PCR Assay and Melt Curve Analysis. Journal of Clinical Microbiology, 2007, 45, 544-547. | 3.9 | 259 |
| 223 | Dissemination and diversity of metallo-Î²-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program. International Journal of Antimicrobial Agents, 2005, 25, 57-61. | 2.5 | 93 |
| 224 | First Isolation of bla VIM-2 in Latin America: Report from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2004, 48, 1433-1434. | 3.2 | 45 |
| 225 | Integron Carrying a Novel Metallo-Î²-Lactamase Gene, bla IMP-16 , and a Fused Form of Aminoglycoside-Resistant Gene aac(6â€²)-30/aac(6â€²)-Ibâ€² : Report from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2004, 48, 4693-4702. | 3.2 | 86 |